Microsoft PowerPoint - AVNT Q4 2023 Earnings Presentation v7 AVIENT CORPORATION F O U R T H Q U A R T E R 2 0 2 3 R E S U L T S A N D 2 0 2 4 F I N A N C I A L G U I D A N C E (NYSE: AVNT) F E B R U A R Y 1 4 , 2 0 2 4 D I S C L A I M E R Forward-Looking Statements Certain statements contained in or incorporated by reference into this presentation constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Additionally, Adjusted EPS excludes the impact of special items and amortization expense associated with intangible assets. 2 O P E N I N G R E M A R K S DR. ASHISH KHANDPUR P R E S I D E N T & C E O 4 5 PORTFOLIO TRANSFORMATION 5 7% 46% 66% 87% 100% 0% 20% 40% 60% 80% 100% 2005 2010 2015 2020 2023 % o f A dj us te d E B IT D A Commodity JVs Distribution Performance Products & Solutions Specialty Businesses Adjusted EBITDA from Specialty Applications SUSTAINABILITY AS A GROWTH DRIVER 7 LONG-TERM REVENUE GROWTH DRIVERS Sustainable Solutions Composites, Healthcare, Asia / LATAM Overlap Other 60%+ Key Growth Drivers Total Company Revenue Growth Drivers Long-Term Growth Rate Sustainable Solutions 8–12% Composites 8–10% Healthcare 8–10% Asia / LATAM 5% Other 0–2% Avient 6% END MARKET OBSERVATIONS ( % O F C O M PA N Y S A L E S ) ENERGY 5% DEFENSE 7% TELECOMMUNICATIONS 4% HEALTHCARE 7% 8 TRANSPORTATION 10% INDUSTRIAL 16% BUILDING & CONSTRUCTION 9% CONSUMER 19% PACKAGING 23% 9 REGIONAL OBSERVATIONS ( % O F C O M PA N Y S A L E S ) 9 US & Canada Latin America EMEA Asia 41% 36% 18% 5% Q 4 2 0 2 3 R E S U L T S Q4 2023 PERFORMANCE VS.

Microsoft PowerPoint - Avient Q4 Earnings and 2021 Outlook PRINT AVIENT CORPORATION F O U R T H Q U A R T E R 2 0 2 0 R E S U L T S A N D 2 0 2 1 F I N A N C I A L G U I D A N C E (NYSE: AVNT) F E B R U A R Y 9 , 2 0 2 1 D I S C L A I M E R 2 Forward-Looking Statements In this presentation, statements that are not reported financial results or other historical information are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Free cash flow conversion calculated as (EBITDA – Capex) / EBITDA Median: 83% Median: 76% H I G H F R E E C A S H F L OW C O N V E R S I O N Avient reflects 2021 estimated EBITDA of $510M and excludes one-time synergy capture CAPEX ($20M) Source: Peer data per Bloomberg market data as of 2021年2月5日 85 87 86 86 81 81 59 92 88 81 79 79 79 76 76 75 73 67 67 64 60 7 A vi e n t P P G K W R R P M F U L A V Y G C P IF F F M C U N V R H X L E M N B N R E C L C E A S H F O E G R A H U N K R A S C L A L B Source: Peer data per Bloomberg market data as of 2021年2月5日 Total Enterprise Value / 2021E EBITDA Our current valuation implies an EBITDA multiple that is significantly below specialty formulator peers and our historic valuations, when the company had considerable exposure to more cyclical and challenging end markets. With the Clariant Masterbatch acquisition and divestment of the PP&S business, our exposure is now concentrated in less-cyclical and high-growth markets, with increased geographic diversification and a more specialized portfolio that can significantly expand EBITDA margins. 24 Avient reflects 2021 estimated EBITDA of $510M O U R VA LUATI O N V E R S U S P E E R S Avient Specialty Formulators Other Chemical/Specialty Companies 9.5 21.1 13.2 13.2 12.0 12.0 9.7 25.2 23.1 14.7 13.5 12.9 11.0 11.0 11.0 10.2 9.6 9.3 9.3 9.1 8.6 8.3 A vi e n t K W R A V Y R P M G C P P P G F U L A L B E C L H X L IF F F M C G R A B N R F O E A S H C E S C L U N V R E M N H U N K R A Median: 11.0xMedian: 12.6x S U M M A RY: W H Y I N V E S T I N AV I E N T ?

C a s e S t u d y T h e P D I D i f f e r e n c e Characterizing the polymer’s viscoelastic properties under conditions that simulate the human body helped PDI to predict creep performance, which identifies the measurable strain put on a polymer over a given period of time. Asset No. 76593C M Y K PDICaseStudy.indd REMAY 76593 trim: 8.5in x 11in and 8.25in x 11.6875in bleed: 8.75in x 11.9375in Digital/IAM 8 . 5 i n 11 .6 8 7 5 in 8 . 7 5 i n 11 .9 3 7 5 in 8 . 2 5 i n 11 in w w w. p o l y m e r d i a g n o s t i c s . c o m Copyright © 2008, Polymer Diagnostics Inc. D e l i v e r i n g R e a l - Wo r l d R e s u l t s Research, development, and optimization of the Freedom® Lumbar Disc will help millions of patients across the world suffering from chronic back pain.

在很宽的频率范围仍保持稳定的射频性能 0 ,0 2 ,0 4 ,0 6 ,0 8 ,0 1 0 ,0 1 2 ,0 0 1 0 2 0 3 0 4 0 5 0 6 0 D ie le ct ri c co n s ta n t F re que nc y [G H z ] P R E P E R M ® P P E 95 0 P R E P E R M ® P P E 80 0 P R E P E R M ® P P E 44 0 P R E P E R M ® P P E 32 0 P R E P E R M ® P P E 26 0 生产过程中批次间的稳定性 * 2018 年芬兰有限公司VTT技术研究中心测量数据 介 电 常 数 损 耗 因 数 介 电 常 数 频率 [GHz] 频率 [GHz] 分批编号 （1250 kg/批次） PREPERM™ PPE950 PREPERM™ PPE800 PREPERM™ PPE440 PREPERM™ PPE320 PREPERM™ PPE260 -- 目标介电常数 -- +/- 2% 3 ,7 6 3 ,7 8 3 ,8 0 3 ,8 2 3 ,8 4 3 ,8 6 3 ,8 8 3 ,9 0 3 ,9 2 3 ,9 4 0 1 2 3 4 5 6 7 8 D ie le ct ri c co n s ta n t P a lle t numbe r (1 2 5 0 k g/pa lle t ) D ie le c t ric c o n s t a nt t a rge t +/ - 2 % 0 ,0 0 0 0 ,0 0 2 0 ,0 0 4 0 ,0 0 6 0 ,0 0 8 0 ,0 1 0 0 1 0 2 0 3 0 4 0 5 0 6 0 L o s s t a n g e n t F re que nc y [G H z ] P R E P E R M ® P P E 95 0 P R E P E R M ® P P E 80 0 P R E P E R M ® P P E 44 0 P R E P E R M ® P P E 32 0 P R E P E R M ® P P E 26 0 0 ,0 0 0 0 ,0 0 2 0 ,0 0 4 0 ,0 0 6 0 ,0 0 8 0 ,0 1 0 0 1 0 2 0 3 0 4 0 5 0 6 0 L o s s t a n g e n t F re que nc y [G H z ] P R E P E R M ® P P E 95 0 P R E P E R M ® P P E 80 0 P R E P E R M ® P P E 44 0 P R E P E R M ® P P E 32 0 P R E P E R M ® P P E 26 0 0 ,0 0 0 0 ,0 0 2 0 ,0 0 4 0 ,0 0 6 0 ,0 0 8 0 ,0 1 0 0 1 0 2 0 3 0 4 0 5 0 6 0 L o s s t a n g e n t F re que nc y [G H z ] P R E P E R M ® P P E 95 0 P R E P E R M ® P P E 80 0 P R E P E R M ® P P E 44 0 P R E P E R M ® P P E 32 0 P R E P E R M ® P P E 26 0 1.844.4AVIENT www.avient.com 版权所有©2022 埃万特公司。

S A F E T Y P ROT E C T I O N B R A N D S A F E T Y G O G G L E G A S K E T • Good adhesion onto polycarbonate (PC) • Flexible and comfortable to wear • FDA compliant • Customized a Shore 43A TPE with good adhesion to PC frame • Delivered soft-touch and non-tacky feel • Complied with FDA 21 CFR 177.2600 Custom Versaflex™ Thermoplastic Elastomers (TPEs) KEY REQUIREMENTS WHY AVIENT?

BHD. 9-3A-1, JLN METRO PERDANA BARAT 1, TMN USAHAWAN KEPONG UTARA, 52100 KUALA LUMPUR WP KUALA LUMPUR A V I E N T C O L O R A N T S M A L A Y S I A S D N .

AVIENT SOLUTION MEDICAL DEVICE MANUFACTURER C O M P R E S S I O N C O N T R O L L E R H O U S I N G G R I P • Good adhesion to PCTG • Comfortable grip combined with ergonomics • Medical regulation compliance • Provided a medical-grade TPE with excellent bonding to PCTG and good chemical resistance • Improved ergonomics and aesthetics with a soft- touch material • Met medical regulation compliance: FDA21 CFR 177.2600 • Delivered good colorability to ensure a stable esthetic KEY REQUIREMENTS OVERMOLDING + REGULATORY SUPPORT LEARN MORE Versollan Thermoplastic Elastomers Copyright © 2024, Avient Corporation.

DUAL-BAND ANTENNA MANUFACTURER P O S I T I O N I N G S Y S T E M • Ceramic replacement • Miniaturization • Moldable • Formulated materials for specific Dk/Df values • Delivered lower signal loss versus ceramic • Enhanced mechanical properties and eliminated secondary processing • Provided stable dielectric performance during injection molding process Edgetek™ Dielectric Constant (Dk) Formulations KEY REQUIREMENTS WHY AVIENT?

HEALTHCARE DEVICE OEM S U R G I C A L S T A P L E R H O U S I N G • Easy-to-mold, durable, and good aesthetics • Excellent disinfection performance and good chemical resistance • Compatible with high- and low-temperature sterilization • Delivered durable and aesthetically pleasing specialty polymer with the added benefit of processing flexibility without retooling • Passed physical, chemical and disinfection tests in different testing conditions which proved good tensile strength and chemical resistance • Achieved consistent molding shape and properties Trilliant™ HC Thermoplastics KEY REQUIREMENTS WHY AVIENT?

AEROSPACE INTERIORS OEM S E A T S P A C E R & A R M R E S T • Weight reduction to increase airliner fuel economy • Meet FAA safety requirements for FST compliance and 16G kinetic survivability • Agility to delivery solution within 8-month compressed product development timeline • Achieved 40% weight reduction generating $16,000 per year reduction in fuel costs • Optimized component designs for long fiber material and conducted FEA validation • Performed prototype molding and testing for load and impact specifications to expedite development Complēt™ Long Carbon Fiber PES Composite KEY REQUIREMENTS WHY AVIENT?